REFERENCES

1. Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 1994;20:1442-9.

2. Engelmann G, Quader J, Teufel U, et al. Limitations and opportunities of non-invasive liver stiffness measurement in children. World J Hepatol 2017;9:409-17.

3. Wong GL-H. Non-invasive assessments for liver fibrosis: the crystal ball we long for. J Gastroenterol Hepatol 2018;33:1009-15.

4. Association for the Study of the Liver. Electronic address: [email protected], European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-98.

5. Stasi C, Milani S. Evolving strategies for liver fibrosis staging: non-invasive assessment. World J Gastroenterol 2017;23:191-6.

6. Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J Hepatol 2012;56:1171-80.

7. Atwell TD, Smith RL, Hesley GK, et al. Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin. AJR Am J Roentgenol 2010;194:784-9.

8. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology 2009;49:1017-44.

9. Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-402.

10. Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63:237-64.

11. Peleg N, Issachar A, Sneh-Arbib O, et al. AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease. Dig Liver Dis 2017;49:1133-8.

12. Wu HM, Sheng L, Wang Q, et al. Performance of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis-primary biliary cholangitis overlap syndrome. World J Gastroenterol 2018;24:737-43.

13. Karlas T, Petroff D, Sasso M, et al. Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. Aliment Pharmacol Ther 2018;47:989-1000.

14. Guo L, Zheng L, Hu L, et al. Transient Elastography (FibroScan) Performs Better Than Non-Invasive Markers in Assessing Liver Fibrosis and Cirrhosis in Autoimmune Hepatitis Patients. Med Sci Monit 2017;23:5106-12.

15. Wilder J, Patel K. The clinical utility of FibroScan(®) as a noninvasive diagnostic test for liver disease. Med Devices Auckl NZ 2014;7:107-14.

16. Buechter M, Kersting S, Gerken G, et al. Enzymatic liver function measured by LiMAx - a reliable diagnostic and prognostic tool in chronic liver disease. Sci Rep 2019;9:13577.

17. Jara M, Bednarsch J, Valle E, et al. Reliable assessment of liver function using LiMAx. J Surg Res 2015;193:184-9.

18. Malinowski M, Jara M, Lüttgert K, et al. Enzymatic liver function capacity correlates with disease severity of patients with liver cirrhosis: a study with the LiMAx test. Dig Dis Sci 2014;59:2983-91.

19. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.

20. Buechter M, Thimm J, Baba HA, et al. Liver maximum capacity: a novel test to accurately diagnose different stages of liver fibrosis. Digestion 2019;100:45-54.